A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Inclusion Criteria:

- Subject must be greater then or equal to 18 years of age.

- Subject must have relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic
Lymphoma.

- Subject has an Eastern Cooperative Oncology Group performance score of less than or
equal to 1.

- Subject must have adequate bone marrow independent of growth factor support per local
laboratory reference range at Screening.

- Subject must have adequate coagulation, renal, and hepatic function, per laboratory
reference range at Screening.

Exclusion Criteria:

- Chronic lymphocytic leukemia or Small Lymphocytic Lymphoma subject has undergone an
allogeneic or autologous stem cell transplant.

- Subject has uncontrolled autoimmune hemolytic anemia or thrombocytopenia.

- Subject has tested positive for human immunodeficiency virus.

- Seropositivity for hepatitis B surface antigen or hepatitis C virus antibody or
ribonucleic acid.

- History of severe allergic or anaphylactic reactions to rituximab.

- Subject has received a live viral vaccine within 6 months prior to the first dose of
study drug.

- Subject has received a monoclonal antibody for anti-neoplastic intent within 8 weeks
prior to the first dose of study drug.

- Subject has received any of the following within 14 days prior to the first dose of
study drug, or has not recovered to less than grade 2 clinically significant adverse
effect(s)/toxicity(s) of the previous therapy:

- Any anti-cancer therapy including chemotherapy, immunotherapy, or radiotherapy;

- Investigational therapy, including targeted small molecule agents.

- Subject has a cardiovascular disability status of New York Heart Association Class
greater then or equal to 2. Class 2 is defined as cardiac disease in which subjects
are comfortable at rest but ordinary physical activity results in fatigue,
palpitations, dyspnea or anginal pain.

- Subject has a significant history of renal, neurologic, psychiatric, pulmonary,
endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in
the opinion of the investigator would adversely affect his/her participating in this
study.

- Subject has a history of other active malignancies other than CLL/SLL within the past
2 years prior to study entry, with the exception of:

- Adequately treated in situ carcinoma of the cervix uteri;

- Basal cell carcinoma of the skin or localized squamous cell carcinoma of the
skin;

- Previous malignancy confined and surgically resected (or treated with other
modalities) with curative intent.

- Subject has malabsorption syndrome or other condition that precludes enteral route of
administration.

- Subject has a history of a prior significant toxicity, other than thrombocytopenia or
neutropenia from another Bcl-2 family protein inhibitor.